Accepted
at 11:32 p.m. Sep, 22, 2025
by
braviboron
Author:
julian_stevenson
Co-authors:
braviboron
Type of change:
Updated content
Rationale for change
Original question seems too easy, so I improved it by adding same dose.
Before
After
Text
Text
Text
Text
Extra

- With reduced dose of apixaban or rivaroxaban, but full dose may be indicated in higher risk patients, such as those with prior unprovoked episodes of venous thromboembolism, APS or active cancer

Extra (Synced)
Empty field
Personal Notes
Empty field
Missed Questions
Empty field
eTG Complete
Empty field
Talley & O'Connor
Empty field
Additional Resources
Empty field
Additional Resources (Synced)
Empty field
Source
- Tran, H.A., Gibbs, H., Merriman, E., Curnow, J.L., Young, L., Bennett, A., Tan, C.W., Chunilal, S.D., Ward, C.M., Baker, R. and Nandurkar, H. (2019), New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med. J. Aust., 210: 227-235. https://doi.org/10.5694/mja2.50004
- At time of authorship, Therapeutic Guidelines refers to the above guideline
One by one
Empty field